November 8, 2024
TOPLINE: Venetoclax–obinutuzumab combination therapy for untreated chronic lymphocytic leukemia (CLL) shows a 6-year progression-free survival (PFS) rate of 53%. The time-to-next-treatment (TTNT) rate is 65%, with […]
November 7, 2024
TOPLINE: Postpartum exercise reduces the severity of depressive and anxiety symptoms. Initiating exercise within 12 weeks postpartum is linked to greater reductions in depressive symptoms. METHODOLOGY: […]
November 7, 2024
TOPLINE: Increased telehealth use in primary care practices is associated with reduced rates of low-value cervical cancer screening and thyroid testing. No significant association is found […]
November 7, 2024
TOPLINE: Black patients with inherited retinal diseases who undergo genetic testing are less likely than White patients to receive a conclusive genetic diagnosis, new research shows. […]
November 7, 2024
TOPLINE: Patients treated for prostate cancer had higher rates of complications, including urinary and sexual issues, than a control group of men. Radiotherapy increases the risk […]
November 7, 2024
TOPLINE: About 1 in 6 women experience symptoms of postpartum depression (PPD) 2 months after cesarean delivery, with certain obstetric factors such as emergency cesarean delivery […]
November 7, 2024
TOPLINE: A phospholipid nanoemulsion–based ocular lubricant applied twice daily is well tolerated, improves the stability of tear film, and alleviates symptoms in patients with dry eye […]
November 7, 2024
TOPLINE: Levonorgestrel intrauterine devices (IUDs) are associated with significantly more reports of acne, alopecia, and hirsutism compared with copper IUDs, with some differences between the available […]
November 7, 2024
TOPLINE: Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; […]